Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Dec 27, 2014; 6(12): 930-938
Published online Dec 27, 2014. doi: 10.4254/wjh.v6.i12.930
Published online Dec 27, 2014. doi: 10.4254/wjh.v6.i12.930
Evaluation of hepatocellular carcinoma development in patients with chronic hepatitis C by EOB-MRI
Shunsuke Nojiri, Kei Fujiwara, Noboru Shinkai, Mio Endo, Takashi Joh, Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi 467-8601, Japan
Author contributions: Nojiri S is the author; Fujiwara K, Shinkai N, Endo M and Joh T contributed to collecting data.
Correspondence to: Shunsuke Nojiri, MD, PhD, Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, Kawasumi 1, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8601, Japan. snojiri@med.nagoya-cu.ac.jp
Telephone: +81-52-8538211 Fax: +81-52-8520952
Received: July 9, 2014
Revised: October 22, 2014
Accepted: November 17, 2014
Published online: December 27, 2014
Revised: October 22, 2014
Accepted: November 17, 2014
Published online: December 27, 2014
Core Tip
Core tip: This manuscript addresses a method of hepatocellular carcinoma (HCC) prediction by using a new technique that evaluates hepatic fibrosis using a noninvasive method (reported recently). This is the first reported study to consider a possible substitute for liver biopsy by using an magnetic resonance imaging (MRI) method (a widespread method in public medical services) for evaluating the risk of occurrence. We propose that this method will become one of the most popular and precise noninvasive methods to predict the occurrence of HCC, and the combination of this MRI method and Fib-4 index may provide a better predictive method of HCC progression.